Document:

<PAGE>

                                                                   EXHIBIT 10.42

                                    AMENDMENT

         This Amendment to Funding Agreement is entered into as of the 30th day
of December, 2003, by and between Tony Frudakis ("Investor") and DNAPRINT
genomics, Inc. (the "Company").

                              W I T N E S S E T H:

         WHEREAS, the parties hereto are parties to a Funding Agreement dated on
or about October 25, 2002, (the "Agreement"), pursuant to which the Investor has
advanced certain funds to the Company; and

         WHEREAS, the parties desire to memorialize the modifications in this
Amendment.

         NOW, THEREFORE, in consideration of the premises and the mutual
covenants contained herein, the parties agree as follows:

                  1.       Capitalized terms used herein but not defined herein
                           shall have the same meaning given to those in the
                           Agreement.

                  2.       The term of the Agreement and the Consideration
                           associated therewith are hereby amended to extend
                           such dates for repayment of any and all funds
                           advanced pursuant to the Agreement, whether or not
                           such advances are represented by independent
                           promissory notes, until December 31, 2004, and the
                           Investor shall take no action to collect any such
                           funds unless and until such funds shall not have been
                           repaid by December 31, 2004.

                  3.       Except as explicitly modified herein, the Agreement
                           shall remain in full force and effect.

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first above written.

                                         DNAPrint genomics, Inc.

                                         By: /s/ Tony Frudakis
                                            ____________________________________

                                         /s/ Tony Frudakis
                                         _______________________________________
                                         Tony Frudakis<PAGE>

                                                                    EXHIBIT 10.8

[PlanVista LOGO]

CORPORATE HEADQUARTERS
4010 Boy Scout Blvd., Suite 200
Tampa, FL  33607
(813) 353-2300
www.planvista.com

                                                                December 4, 2003

                             PERSONAL & CONFIDENTIAL

Mr. Jeffrey L. Markle
16326 Healthrow Avenue
Tampa, Florida   33629

Dear Mr. Markle:

      This letter serves to confirm certain terms and conditions with regard to
your employment with PlanVista Corporation, its successors and assigns (the
"Company"). As you know, the Company and ProxyMed, Inc. ("ProxyMed") intend to
enter into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to
which the Company will become a wholly-owned subsidiary of ProxyMed on the day
and time the merger becomes effective (the "Effective Date"). ProxyMed would
like to provide the terms and conditions of your employment with the Company and
ProxyMed upon the consummation of the Merger. Accordingly, attached hereto
please find a copy of ProxyMed's form of employment agreement (the "Form of
Employment Agreement"). Except to the extent qualified by the terms and
conditions specified in paragraphs number 1 through 6 below (the "Qualifying
Terms"), the terms and conditions of the Form of Employment Agreement are
generally not subject to modification, except as approved in writing in advance
by the Compensation Committee of ProxyMed's Board of Directors (the
"Compensation Committee").

      Set forth below is a summary of the Qualifying Terms of your employment
with the Company and ProxyMed after the Effective Date.

      1.    Unless otherwise agreed by the parties in writing, your title will
            be President and Chief Operating Officer of the Company and Senior
            Vice President ("SVP") of ProxyMed, reporting to Nancy J. Ham,
            President and Chief Operating Officer of ProxyMed.

      2.    Your annual salary as President and COO of the Company and SVP of
            ProxyMed shall be $197,000, minus all applicable federal, state and
            local taxes and shall be paid in accordance with ProxyMed's then
            applicable policies.

      3.    You shall not be entitled to receive any options as a result of
            executing this letter. However, you shall be eligible to participate
            on the same terms as other SVP's of ProxyMed in all
            ProxyMed-sponsored benefit plans, such as health, dental, life, and

<PAGE>

Mr. Jeffrey L. Markle
December 4, 2003
Page 2

            STD/LTD insurances, and shall accrue twenty-two (22) days of paid
            time off per year, pro-rated for your first year.

      4.    As a further incentive and inducement to you to continue your
            employment with the Company and ProxyMed and to devote your best
            efforts to the business and affairs of the Company and ProxyMed, you
            shall be entitled to and may earn such bonuses as may be awarded
            from time to time by the Board of Directors of ProxyMed, sitting as
            a whole or in committee, in its sole discretion, including pursuant
            to any bonus plan, including a possible change of control bonus
            ("Bonus Plan") implemented by ProxyMed, and to participate in any
            stock option plans ("Stock Option Plans") or other Bonus Plans
            (collectively with the Stock Option Plans, the "Plans") which
            ProxyMed may now have, or in the future develop, provided you
            qualify for eligibility under the terms of such Plans. In addition,
            the parties will negotiate an appropriate provision in your
            Employment Agreement (as defined herein) that provides for
            accelerated vesting of some or all of your stock options upon a
            termination of your employment without cause.

      5.    You will be required to execute the attached Non-Disclosure,
            Non-Solicitation and Invention Agreement ("Associate NDA") on or
            before the Effective Date. As of the Effective Date, you will also
            be required to abide by the Company's (and/or ProxyMed's)
            then-current published policies and procedures, the receipt and
            review of which you must acknowledge in writing.

      6.    Unless waived by ProxyMed in writing, the Terms of Employment (as
            defined below) shall be contingent upon (i) your execution and
            delivery to ProxyMed's legal department of the Associate NDA and
            (ii) approval by ProxyMed's Compensation Committee.

      You acknowledge and agree that you have read and understand the terms and
conditions set forth herein, including the Qualifying Terms (jointly, the "Terms
of Employment"), and that no agreements or representations, oral or otherwise,
express or implied, have been made to you that are not set forth expressly in
this letter. Furthermore, you acknowledge and agree that such Terms of
Employment (i) are binding upon you, ProxyMed and the Company and (ii) modify
and amend any employment agreement currently in effect between you and the
Company until the earlier of (a) six (6) months from the date of this letter or
(b) until the execution of an Employment Agreement (as defined herein), during
which time neither party may terminate the Terms of Employment other than for
cause with ninety (90) days prior written notice. The foregoing notwithstanding,
upon the first to occur of either of the aforesaid (a) or (b), this letter shall
immediately terminate and of no force or effect. You agree that you will
cooperate and negotiate in good faith with ProxyMed and the Company with the
objective of entering into a definitive employment agreement with both the
Company and ProxyMed prior to the Effective Date, relating to your employment on
or after the Effective Date, on terms substantially similar to the Terms of
Employment (hereinafter, the "Employment Agreement").

<PAGE>
Mr. Jeffrey L. Markle
December 4, 2003
Page 3

      You acknowledge and agree that, unless otherwise waived by Mr. Hoover in
writing, upon execution of the Employment Agreement or the expiration of six (6)
months from the date of this letter, whichever occurs first, in addition to the
termination of this letter, your employment with the Company pursuant to the
terms of that certain Employment and Noncompetition Agreement dated June 1,
2001, as amended on May 22, 2003, and this letter shall automatically and
immediately terminate and be of no further force or effect. Upon such
terminations, neither the Company nor ProxyMed shall have any ongoing
obligations, financial or otherwise, arising from or relating to such employment
agreements, except for the payment to you of earned wages and vacation, or for
any post-termination, surviving obligations you may have to the Company or
ProxyMed, however arisen.

      If you are in agreement with the Terms of Employment stated in pages 1 and
2 of this letter, please sign duplicates of this letter and return it to my
attention on or before December 8, 2003.

                                   Sincerely,

                                   PLANVISTA CORPORATION

                                   By:    /s/ PHILLIP S. DINGLE
                                          ------------------------------

                                   Title: Chairman and CEO
                                          ------------------------------

                                   PROXYMED, INC.

                                   By:    /s/ NANCY J. HAM
                                          ------------------------------

                                   Title: President
                                          ------------------------------

/ir
Enclosures

cc: Rafael G. Rodriguez

                                   AGREED TO:

                                   By:  /s/ JEFFREY L. MARKLE
                                        ----------------------------------
                                        SIGNATURE

                                   Date  DECEMBER 18, 2003
                                         ---------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]